Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer.
- Author:
Yang ZHANG
1
;
Bo-Han LEI
2
;
Qing ZOU
3
;
Qing-Yi ZHU
1
;
Zi-Jie LU
1
;
Yue WANG
4
Author Information
1. Department of Urology, Jiangsu Provincical Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, China.
2. School of Basic Medical Science and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.
3. Department of General Surgery, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210041, China.
4. Department of Internal Medicine of Traditional Chinese Medicine， The First School of Clinical Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, China.
- Publication Type:Journal Article
- Keywords:
chemotherapy;
prostate cancer;
prostate-specific antigen;
integrated traditional Chinese and Western medicine
- MeSH:
Anilides;
administration & dosage;
Antineoplastic Agents, Hormonal;
therapeutic use;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Docetaxel;
Drug Administration Schedule;
Goserelin;
administration & dosage;
Humans;
Male;
Nitriles;
administration & dosage;
Prednisone;
administration & dosage;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms, Castration-Resistant;
blood;
drug therapy;
Taxoids;
administration & dosage;
Tosyl Compounds;
administration & dosage;
Treatment Outcome
- From:
National Journal of Andrology
2017;23(10):922-927
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effects of integrated traditional Chinese and Western medicine in the treatment of castration-resistant prostate cancer (CRPC).
METHODS:A total of 54 CRPC patients were randomly divided into a control and a trial group, all treated by endocrine therapy (oral Bicalutamide at 50 mg per d plus subcutaneous injection of Goserelin at 3.6 mg once every 4 wk) and chemotherapy (intravenous injection of Docetaxel at 75 mg/m2 once every 3 wk plus oral Prednisone at 5 mg bid), while the latter group by Fuyang Huayu Prescription (a Traditional Chinese Medicine ［TCM］ prescription for tonifying yang and dispersing blood stasis) in addition, for a course of 24 weeks. Comparisons were made between the two groups of patients in the level of serum prostate-specific antigen (PSA), Karnofsky physical condition scores, function assessment of cancer therapy-prostate (FACT-P) scores, and TCM symptoms scores before and after 12 or 24 weeks of treatment.
RESULTS:Compared with the baseline, the serum PSA level was significantly decreased after 12 weeks of treatment both in the control (［25.9 ± 39.3］ vs ［20.0 ± 21.1］ μg/L, P <0.05) and in the trial group (［22.1 ± 33.9］ vs ［17.9 ± 19.1］ μg/L, P <0.05), with no statistically significant differences between the two groups (P >0.05). At 24 weeks, however, the PSA levels in the control and trial groups were slightly increased to (23.1 ± 28.4) and (19.6 ± 23.5) μg/L, respectively, with no statistically significant differences in between (P >0.05). Karnofsky, FACT-P and TCM symptoms scores were all markedly improved in the trial group after 12 weeks of treatment (P <0.05) and remained stable at 24 weeks, but not in the control group either at 12 or at 24 weeks (P >0.05).
CONCLUSIONS:TCM Fuyang Huayu Prescription combined with endocrine therapy and chemotherapy is effective for CRPC.
